Literature DB >> 25811955

New organochalcogen multitarget drug: synthesis and antioxidant and antitumoral activities of chalcogenozidovudine derivatives.

Diego de Souza1, Douglas O C Mariano1, Fernanda Nedel2, Eduarda Schultze2, Vinícius F Campos2, Fabiana Seixas2, Rafael S da Silva1, Taiana S Munchen1, Vinicius Ilha1, Luciano Dornelles1, Antonio L Braga3, João B T Rocha1, Tiago Collares2, Oscar E D Rodrigues1.   

Abstract

In this article we present the synthesis, characterization, and in vitro biological and biochemical activities of new chalcogenozidovudine derivatives as antioxidant (inhibition of TBARS in brain membranes and thiol peroxidase-like activity) as well as antitumoral agents in bladder carcinoma 5637. A prominent response was obtained for the selected chalcogenonucleosides, showing effective antioxidant and antitumoral activities.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25811955     DOI: 10.1021/jm5015296

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Synthesis, antioxidant and antitumoral activities of 5'-arylchalcogeno-3-aminothymidine (ACAT) derivatives.

Authors:  Raquel Mello da Rosa; Bruna Candia Piccoli; Fernanda D'Avila da Silva; Luciano Dornelles; João B T Rocha; Mariana Souza Sonego; Karine Rech Begnini; Tiago Collares; Fabiana K Seixas; Oscar E D Rodrigues
Journal:  Medchemcomm       Date:  2016-12-22       Impact factor: 3.597

Review 2.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

3.  A Simple Zinc-Mediated Method for Selenium Addition to Michael Acceptors.

Authors:  Francesca Giulia Nacca; Bonifacio Monti; Eder João Lenardão; Paul Evans; Claudio Santi
Journal:  Molecules       Date:  2020-04-26       Impact factor: 4.411

4.  Revitalizing the AZT Through of the Selenium: An Approach in Human Triple Negative Breast Cancer Cell Line.

Authors:  Mônica Silveira Wagner; Eduarda Schultze; Thais Larre Oliveira; Priscila Marques Moura de Leon; Helena Strelow Thurow; Vinicius Farias Campos; Isabel Oliveira; Diego de Souza; Oscar Endrigo Dorneles Rodrigues; Tiago Collares; Fabiana Kömmling Seixas
Journal:  Front Oncol       Date:  2018-11-14       Impact factor: 6.244

Review 5.  Selenides and Diselenides: A Review of Their Anticancer and Chemopreventive Activity.

Authors:  Mónica Álvarez-Pérez; Wesam Ali; Małgorzata Anna Marć; Jadwiga Handzlik; Enrique Domínguez-Álvarez
Journal:  Molecules       Date:  2018-03-10       Impact factor: 4.411

6.  Diselenides and Benzisoselenazolones as Antiproliferative Agents and Glutathione-S-Transferase Inhibitors.

Authors:  Dorota Krasowska; Nunzio Iraci; Claudio Santi; Józef Drabowicz; Marcin Cieslak; Julia Kaźmierczak-Barańska; Martina Palomba; Karolina Królewska-Golińska; Jakub Magiera; Luca Sancineto
Journal:  Molecules       Date:  2019-08-11       Impact factor: 4.411

Review 7.  Synthetic strategies for aryl/heterocyclic selenides and tellurides under transition-metal-catalyst free conditions.

Authors:  Debasish Kundu
Journal:  RSC Adv       Date:  2021-02-10       Impact factor: 3.361

Review 8.  Therapeutic Benefits of Selenium in Hematological Malignancies.

Authors:  Melanie A Ehudin; Upendarrao Golla; Devnah Trivedi; Shobha D Potlakayala; Sairam V Rudrabhatla; Dhimant Desai; Sinisa Dovat; David Claxton; Arati Sharma
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

9.  Overcoming MDR by Associating Doxorubicin and pH-Sensitive PLGA Nanoparticles Containing a Novel Organoselenium Compound-An In Vitro Study.

Authors:  Letícia Bueno Macedo; Daniele Rubert Nogueira-Librelotto; Daniela Mathes; Josiele Melo de Vargas; Raquel Mello da Rosa; Oscar Endrigo Dorneles Rodrigues; Maria Pilar Vinardell; Montserrat Mitjans; Clarice Madalena Bueno Rolim
Journal:  Pharmaceutics       Date:  2021-12-29       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.